Mechanistic study of pancreatic cancer cell radioresistance conferred by Aurora-A

孙会贞; 杨恭

doi:10.3969/j.issn.1007-3969.2013.12.007

您当前的位置：

首页 >

文章列表页 >

Mechanistic study of pancreatic cancer cell radioresistance conferred by Aurora-A

更新时间：2025-12-31

- Mechanistic study of pancreatic cancer cell radioresistance conferred by Aurora-A
- China Oncology Vol. 23, Issue 12, Pages: 974-979(2013)
- 作者机构：
  
  复旦大学附属肿瘤医院实验研究中心，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2013.12.007
  CLC：
- Published Online：17 February 2014，
  
  Published：17 February 2013
- 稿件说明：
移动端阅览
孙会贞,杨恭. Aurora-A促进胰腺癌细胞放射抵抗的机制研究[J]. 中国癌症杂志, 2013, 23(12): 974-979.

孙会贞, 杨恭. Mechanistic study of pancreatic cancer cell radioresistance conferred by Aurora-A[J]. China Oncology, 2013, 23(12): 974-979.
孙会贞,杨恭. Aurora-A促进胰腺癌细胞放射抵抗的机制研究[J]. 中国癌症杂志, 2013, 23(12): 974-979. DOI： 10.3969/j.issn.1007-3969.2013.12.007.

孙会贞, 杨恭. Mechanistic study of pancreatic cancer cell radioresistance conferred by Aurora-A[J]. China Oncology, 2013, 23(12): 974-979. DOI： 10.3969/j.issn.1007-3969.2013.12.007.

摘要

背景与目的：Aurora-A属于丝氨酸和苏氨酸蛋白激酶家族，其异常表达可导致肿瘤发生及其对放射线的抵抗，本研究旨在探讨Aurora-A与细胞放射敏感的相关性。方法：用Aurora-A激酶抑制剂处理Capan-1细胞，检测细胞增殖、锚定非依赖性生长和细胞周期及其周期相关蛋白的变化；处理的细胞同时用γ线照射，然后用流式细胞术检测细胞凋亡。结果：Aurora-A激酶抑制剂处理后，Capan-1细胞生长速度减慢，克隆形成率降低；Aurora-A抑制可引起细胞周期G

/S以及G

/M期转化阻滞，Cyclin D1、CDK2和CDK6表达下降。Aurora-A激酶抑制剂处理后可以提高放射线照射诱导的细胞凋亡率。结论：Aurora-A激酶抑制剂可抑制胰腺癌细胞增殖，阻滞细胞周期，促进细胞对放射线照射的敏感性。因此，Aurora-A可能是胰腺癌放射治疗增敏的靶向分子之一。

Abstract

Background and purpose: Aurora-A is a member of serine/threonine kinase family. The abnormal expression of Aurora-A induces tumorigenesis and radioresistance. This study was aimed to investigate the association of Aurora-A with radioresistance. Methods: Capan-1 cells were treated with Aurora-A kinase inhibitor

and then used to test cell proliferation

anchorage independent assay

cell cycle

and cell cycle regulatory proteins. Treated cells were also used to detect cell apoptosis after γ-irradiation. Results: Cell growth and colony number in soft agar were decreased after treatment with Aurora-A inhibitor. Treatment of cells with Aurora-A inhibitor also down-regulated the expression of Cyclin D1

CDK2 and CDK6 to induce cell cycle arrest at G

/S and G

/M phases

but promoted cell apoptosis a

fter γ-irradiation. Conclusion: Treatment of pancreatic cancer cells with Aurora-A kinase inhibitor blocks cell proliferation and cell cycle progression

and promotes sensitivity of cells to radiation. Thus

Aurora-A may be used as one of therapeutic targets to increase the sensitivity of pancreatic cancer radiotherapy.

关键词

Keywords

references

Views

1724

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A research on the mechanism of SERPINA3 promoting malignant progression and gemcitabine resistance of pancreatic cancer by inhibiting ferroptosis

Effect of liposome binding antisense oligonucleotide BP1003 on albumin-bound paclitaxel sensitivity in pancreatic cancer cells by inhibiting STAT3

New advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2024

An exploratory study of INPP4B, a biomarker of gemcitabine chemoresistance in pancreatic cancer

Research on uPAR promoting proliferation, migration, and chemoresistance of pancreatic cancer by inhibiting autophagy via MAPK signaling

Related Author

Yuan HE

Juncheng GUO

Zhibin YE

Xiaohu WANG

Haonan LI

Jingbiao HUANG

Hua FU

Guochao ZHOU

Related Institution

Department of Gastrointestial Surgery, Hebei General Hospital

Department of Gastrointestial Surgery, Heping Hospital Affiliated to Changzhi Medical College

The First Clinical College of Changzhi Medical College

Department of Hepatology and Gallbladder, Xiangxi Autonomous Prefecture People’s Hospital, Xiangxi

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai Pancreatic Cancer Institute, Shanghai Key Laboratory of Precision Medicine for Pancreatic Cancer, Pancreatic Cancer Institute, Fudan University

AI问答

⁰